Tag Archives: SERAPHIN
May 2015 Br J Cardiol 2015;22(suppl 1):S2–S15 doi:10.5837/bjc.2015.s01
Pulmonary hypertension in UK clinical practice: an update
Dr J Simon R Gibbs, Dr J Gerry Coghlan, Dr David G Kiely, Dr S John Wort
(more…)
March 2014 Br J Cardiol 2014;21:16
In brief
BJCardio Staff
New drugs for diabetes A new DPP-4i for the management of type 2 diabetes, alogliptin (Vipidia®) has been launched by Takeda in the UK following data from EXAMINE, an outcome trial conducted in high risk acute coronary syndrome patients (see Br J Cardiol 2013;4:131) where the drug significantly reduced glucose levels and also demonstrated cardiovascular safety. Alogliptin and the fixed-dose combination product alogliptin and metformin (Vipdomet®) are now available in the UK. Alogliptin is licensed for the treatment of type 2 diabetes mellitus in adults aged 18 years and older to improve glycaemic control in combination with other glucose-lo
For healthcare professionals only
